These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35058314)

  • 1. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
    Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
    J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
    Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
    Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K
    Iwamoto N; Sasaki J; Ohno S; Aoki K; Usui Y; Inuki S; Ohno H; Oishi S
    Bioorg Med Chem; 2024 Feb; 99():117585. PubMed ID: 38219557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry.
    Saito M; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):157-162. PubMed ID: 35736625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
    Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
    Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells.
    Vendrame E; Seiler C; Ranganath T; Zhao NQ; Vergara R; Alary M; Labbé AC; Guédou F; Poudrier J; Holmes S; Roger M; Blish CA
    AIDS; 2020 May; 34(6):801-813. PubMed ID: 32028328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research Progress of Immune Checkpoint TIGIT in Lung Cancer Immunotherapy].
    Wu J; Ren D; Bi H; Yi B; Wang H
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):819-827. PubMed ID: 36419396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
    Lupo KB; Yao X; Borde S; Wang J; Torregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; McIntosh M; Matosevic S
    Nat Commun; 2024 Mar; 15(1):1909. PubMed ID: 38429294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
    Hasan MF; Campbell AR; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Cash CA; Eloriaga JE; Kumar S; Andersen BW; Naeimi Kararoudi M; Tullius BP; Lee DA; Copik AJ
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38081778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
    Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
    Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking TIGIT/CD155 signalling reverses CD8
    Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
    J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
    Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
    Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.